Table 1.

Patient information for the different cohorts. Continuous variables are represented by mean values and ranges by ($q_{25}$–$q_{75}$), with $q_{25}$ and $q_{75}$ being the 25th and 75th percentiles, respectively.

2lClinical Variable		Training Set		Validation Set	Test Set
Cohort		OPC	HNSCC	HN PET-CT	HN1
Number of patients		412	263	90	80
HPV: pos/neg		290/122	223/40	71/19	23/57
HPV status
Age
pos		58.81 (52.00–64.75)	57.87 (52.00–64.00)	62.32 (58.00–66.00)	57.52 (52.00–62.50)
neg		64.82 (58.00–72.75)	60.02 (54.50–67.25)	59.11 (49.50–69.50)	60.91 (56.00–66.00)
Sex: Female/Male
pos		47/243	32/191	14/56	5/18
neg		34/88	15/25	4/15	12/45
T-stage: T1/T2/T3/T4
pos		46/93/94/57	60/93/41/29	10/37/15/9	4/8/9/8
neg		9/35/43/35	6/12/12/10	3/4/8/4	9/16/9/23
N-stage: N0/N1/N2/N3
pos		33/22/215/20	19/30/170/4	11/10/47/3	6/2/15/0
neg		36/16/62/8	5/2/31/2	2/1/13/3	14/10/31/2
Tumor size [cm${}^3$]
pos		29.35 (10.52–37.78)	11.78 (3.94–14.04)	34.63 (14.91–41.77)	23.00 (10.83–34.29)
neg		36.99 (15.72–45.35)	23.57 (5.80–22.85)	35.09 (17.32–47.82)	40.19 (11.77–54.42)
transversal voxel spacing [mm]		0.97 (0.98–0.98)	0.59 (0.49–0.51)	1.06 (0.98–1.17)	0.98 (0.98–0.98)
longitudinal voxel spacing [mm]		2.00 (2.00–2.00)	1.53 (1.00-2.50)	2.89 (3.00–3.27)	2.99 (3.00–3.00)
manufacturer
	GE Med. Sys.	272	238	45	0
	Toshiba	138	3	0	0
	Philips	2	12	45	0
	CMS Inc.	0	0	0	43
	Siemens	0	4	0	37
	other	0	6	0	0